{
    "clinical_study": {
        "@rank": "43607", 
        "arm_group": [
            {
                "arm_group_label": "Lisdexamfetamine", 
                "arm_group_type": "Active Comparator", 
                "description": "Lisdexamfetamine or Vyvanse"
            }, 
            {
                "arm_group_label": "Sugar Pill", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo pill, capsules"
            }
        ], 
        "brief_summary": {
            "textblock": "This study seeks to assess the effects of lisdexamfetamine (trademark name: Vyvanse; LDX) on\n      executive function and prefrontal cortex activation in menopausal women ages 45-57, who\n      report subjective cognitive difficulties. This protocol will recruit women from Dr.\n      Epperson's ongoing study, Protocol #812470, to examine the impact of LDX on brain activation\n      during performance of cognitive tasks specifically probing prefrontal cortex function."
        }, 
        "brief_title": "LDX and Functional Magnetic Resonance Imaging (fMRI in Menopausal Women", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Menopause", 
            "Brain Activity", 
            "Cognition"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Have no previous or present history of a DSM-IV psychiatric or substance dependence\n             disorder within the previous year, according to the Structured Clinical Interview for\n             Diagnosis- DSM-IV (SCID)-Non-Patient Version;\n\n          2. Are within 5 years of last menstrual period (LMP);\n\n          3. Have a follicular stimulating hormone level (FSH) of 20 IU/ml;\n\n          4. Are able to give written informed consent;\n\n          5. Must have clear urine toxicology screen upon recruitment;\n\n          6. Are fluent in written and spoken English;\n\n          7. Are right-handed;\n\n          8. Negative urine pregnancy test if still menstruating.\n\n        Exclusion Criteria:\n\n          1. Mini-mental status exam score of less than or equal to 24;\n\n          2. Presence of a psychiatric disorder within previous year or a life time history of\n             ADHD or psychotic disorder including bipolar disorder, schizoaffective disorder, and\n             schizophrenia;\n\n          3. Lifetime history of drug addiction or abuse, except nicotine;\n\n          4. Regular use of other psychotropic medication;\n\n          5. Regular use (more than once a week) of alcohol that is less than 3 drinks/day;\n\n          6. Presence of a contraindication to treatment with stimulant medication unless the\n             condition is controlled with medication; this would include the presence of\n             uncontrolled hypertension, coronary disease, atrial fibrillation, and arrhythmia;\n\n          7. History of seizures;\n\n          8. History of cardiac disease including known cardiac defect or conduction abnormality;\n\n          9. Abnormal electrocardiogram during screening;\n\n         10. Use of estrogen therapy within previous 2 months;\n\n         11. Current pregnancy or planning to become pregnant;\n\n         12. Metallic implant;\n\n         13. Claustrophobia."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "14", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01977625", 
            "org_study_id": "814735"
        }, 
        "intervention": {
            "arm_group_label": "Lisdexamfetamine", 
            "description": "The overall objective of this study is to assess the effects of LDX on brain activation patterns during tasks of sustained attention and working memory in menopausal women.", 
            "intervention_name": "Lisdexamfetamine", 
            "intervention_type": "Drug", 
            "other_name": "Vyvanse\u00ae"
        }, 
        "intervention_browse": {
            "mesh_term": "Dextroamphetamine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Menopause", 
            "fMRI", 
            "Vyvanse"
        ], 
        "lastchanged_date": "May 2, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19104"
                }, 
                "name": "University of Pennsylvania, Penn Center for Womens Behavioral Wellness"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Utilizing fMRI to Determine the Effects of Vyvanse\u00ae on Memory, Attention, and Brain Activity in Menopausal Women", 
        "overall_official": {
            "affiliation": "University of Pennsylvania", 
            "last_name": "C. Neill Epperson, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To assess the effects of LDX on gamma aminobutyric acid (GABA) and glutamate levels as well as brain activation patterns in the prefrontal cortex (PFC) of menopausal aged women during tasks that utilize working memory and sustained attention. Cognitive domains such as attention, concentration, organization, planning, working memory, initiation of appropriate actions and inhibition of inappropriate actions are considered executive functions. This study will assess the extent to which GABA levels and brain activation patterns in menopausal women differ when treated with LDX versus placebo. We will consider these findings in light of the literature regarding stimulant treatment effects on brain activation in adults with attention deficit hyperactivity disorder (ADHD).", 
            "measure": "Effects of LDX on brain activation during tasks of sustained attention and working memory", 
            "safety_issue": "No", 
            "time_frame": "10 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01977625"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Pennsylvania", 
            "investigator_full_name": "C. Neill Epperson", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "results_reference": {
            "PMID": "21293309", 
            "citation": "Epperson CN, Pittman B, Czarkowski KA, Bradley J, Quinlan DM, Brown TE. Impact of atomoxetine on subjective attention and memory difficulties in perimenopausal and postmenopausal women. Menopause. 2011 May;18(5):542-8. doi: 10.1097/gme.0b013e3181fcafd6."
        }, 
        "secondary_outcome": {
            "description": "To assess the extent to which the effects of LDX on brain activation patterns are correlated with improvement in cognitive symptoms as reported by Brown Attention Deficit disorder (BADDS) scores and performance on cognitive tests measuring memory and sustained attention.", 
            "measure": "Effects of LDX on performance of cognitive tasks", 
            "safety_issue": "No", 
            "time_frame": "10 weeks"
        }, 
        "source": "University of Pennsylvania", 
        "sponsors": {
            "collaborator": {
                "agency": "Shire", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of Pennsylvania", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}